The NIH’s RECOVER initiative just held its 2nd annual workshop-- Pathways to Treatment — and here’s what you need to know. In this episode, Dr Khan shares key updates on Long COVID research from RECOVER 2025, including patient voices, new treatments under study, and where the research is headed next. Listen to Episode 19: Low Dose Naltrexone We’ll cover: ✔️ The role of patient advocates in shaping research ✔️ Interventions under study: low-dose naltrexone, baricitinib, GLP-1 receptor agonists, and stellate ganglion blocks ✔️ Challenges with access and equity in treatment ✔️ What’s next for clinical trials in Long COVID As both a physician and a patient with Long COVID, Dr Khan brings you a unique perspective on what this research means for patients, clinicians, and the future of care. 🔔 Subscribe for more updates on Long COVID research, treatments, and patient perspectives. 👍 Like this episode if you find it helpful, and share it with others navigating Long COVID. More resources: 👉 Learn more about RECOVER: https://recovercovid.org 👉 Follow my work on Long Covid, MD: longcovidmd.substack.com Keywords: Long COVID research update, RECOVER 2025, NIH RECOVER TLC workshop, Long COVID new treatments, low dose naltrexone Long COVID, GLP-1 Long COVID, baricitinib Long COVID, stellate ganglion block Long COVID, Long COVID patient advocacy, Long Covid MD Support the show Subscribe for free written summaries of each episode, resources, and more. LongCovidMD.substack.com/subscribe Support by donating at BuyMeACoffee
